Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,500 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $65.79, for a total value of $361,845.00. Following the sale, the insider owned 211,148 shares of the company’s stock, valued at approximately $13,891,426.92. This represents a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, January 7th, Carl Dambkowski sold 18,700 shares of Apogee Therapeutics stock. The stock was sold at an average price of $77.84, for a total transaction of $1,455,608.00.
• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.00, for a total transaction of $817,500.00.

Apogee Therapeutics Stock Down 5.8%

APGE traded down $4.01 during trading on Wednesday, hitting $64.88. The company’s stock had a trading volume of 755,420 shares, compared to its average volume of 1,035,841. The business’s 50 day simple moving average is $75.43 and its 200-day simple moving average is $56.13. The firm has a market cap of $4.43 billion, a PE ratio of -14.81 and a beta of 1.42. Apogee Therapeutics Inc. has a one year low of $26.20 and a one year high of $84.56.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. Equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on APGE shares. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Wednesday, January 21st. BTIG Research set a $137.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, January 6th. Royal Bank Of Canada downgraded shares of Apogee Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $70.00 to $83.00 in a research report on Thursday, January 22nd. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Apogee Therapeutics in a research note on Tuesday, December 9th. They set a “buy” rating and a $103.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $104.58.

Hedge Funds Weigh In On Apogee Therapeutics

Several institutional investors have recently bought and sold shares of APGE. Strs Ohio purchased a new stake in Apogee Therapeutics in the 4th quarter worth $249,000. Jennison Associates LLC bought a new stake in shares of Apogee Therapeutics in the fourth quarter worth about $43,675,000. State of New Jersey Common Pension Fund D bought a new position in Apogee Therapeutics during the fourth quarter valued at approximately $821,000. Boyer Financial Services Inc. purchased a new position in Apogee Therapeutics during the 4th quarter valued at approximately $237,000. Finally, Comerica Bank increased its stake in Apogee Therapeutics by 1.0% in the 4th quarter. Comerica Bank now owns 35,872 shares of the company’s stock worth $2,708,000 after acquiring an additional 338 shares during the last quarter. 79.04% of the stock is owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.